AIM
RDHL

Acrospire Investment Management’s Redhill Biopharma RDHL Stock Holding History

Acrospire Investment Management’s Portfolio RDHL Stock Details RDHL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-1
Closed -$12K – 1115
2017
Q2 		$12K Hold
1
– – 0.01% 1747
2017
Q1 		$6K Buy
+1
New +$9.99K 0.01% 1977
2016
Q4 		– Hold
0
– -$6K – 2385
2016
Q3 		– Sell
-1
Closed -$14K – 1798
2016
Q2 		$12K Hold
1
– – 0.01% 1706
2016
Q1 		$9K Buy
+1
New +$10.5K 0.01% 1772

Other funds holding RDHL

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
MMH
Menora Mivtachim Holdings Ramat Gan, Israel $21.1B AUM 40.03% 1-Year Est. Return
MIFH
Migdal Insurance & Financial Holdings Petach Tikva, Israel $11.5B AUM 52.5% 1-Year Est. Return
BHB
Bank Hapoalim BM Tel Aviv, Israel $652M AUM 19.01% 1-Year Est. Return
CS
Candriam SCA Strassen, Luxembourg, Luxembourg $19.3B AUM 39.18% 1-Year Est. Return
DADC
D.A. Davidson & Co Great Falls, Montana $18.1B AUM 24.63% 1-Year Est. Return
ISL
Ingalls & Snyder LLC New York $2.83B AUM 21.61% 1-Year Est. Return
FM
Family Management New York $834M AUM 20.83% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
OC
Oppenheimer & Co New York $8.21B AUM 28.81% 1-Year Est. Return

Acrospire Investment Management's RDHL Position: Q3 2017 in Review

Acrospire Investment Management sold out of Redhill Biopharma (RDHL) in Q3 2017, closing a stake of 1 share — an estimated $12K sold.

Acrospire Investment Management first reported a position in RDHL in Q1 2016 and held it in 4 quarters. The position peaked at $12K in Q2 2017. 23 funds tracked by Wall St. Rank hold RDHL as of Q3 2017.

  • Acrospire Investment Management reported no remaining Redhill Biopharma position as of Q3 2017 after selling out during the quarter.
  • Acrospire Investment Management sold 1 Redhill Biopharma share in Q3 2017, an estimated $12K.
  • Acrospire Investment Management first reported a position in Redhill Biopharma in Q1 2016 and held it in 4 quarters.
  • Acrospire Investment Management's Redhill Biopharma position peaked at $12K in Q2 2017.
  • 23 funds tracked by Wall St. Rank held Redhill Biopharma as of Q3 2017.

Based on Acrospire Investment Management's 13F filing for Q3 2017, filed 26 Oct 2017.